Patients with immunodeficiency are prone to lympho proliferative disorders. Such conditions are categorized by WHO as "immunodeficiencyassociated lymphop roliferative disorders" (1) . Furthermore, lymphopro liferative conditions in nonposttransplant patients receiving immunosuppressive therapy are subcategori zed as "other iatrogenic immunodeficiencyassociated lymphoproliferative disorders" (1) . This subcategory comprises a broad spectrum of lymphoproliferative dis orders, including lymphomas (1, 2) . We report here a rare case of extranasal NK/Tcell lymphoma (ENKTL) associated with antitumour necrosis factor (antiTNF) and thiopurine therapy.
Extranodal natural killer/Tcell lymphoma, nasal type (ENNK/TNT) is a rare Tcell lymphoma that has strong associations with EpsteinBarr virus (EBV). When ENNK/TNT presents at locations other than the upper aerodigestive tract, it is called ENKTL and tends to be highly aggressive (1) . In patients with inflammatory bo wel disease receiving antiTNF and thiopurine therapy, the risk of lymphoma has been under constant debate (3) (4) (5) . The present case suggests that EBVassociated NK/Tcell lymphoma may be a rare, but lifethreatening complication in patients who receive antiTNF and thio purine therapy.
CASE REPORT
A 42yearold woman had been admitted for treatment of a retractable gastric ulcer arising from atypical enteroBehcet's disease and was referred to our department with tender ery thema on her legs that had appeared suddenly 3 days earlier. She had a medical history of polymyositis. The patient had been taking prednisolone, 10-20 mg daily, for approximately 5 years. She had been receiving antiTNF antibody therapy for a total of 3 months; adalimumab was used twice at 80 mg and 160 mg biweekly, and this biologic was later switched to infliximab, 300 mg monthly, for 2 months. In addition, she had been treated with azathioprine, 50 mg daily, for 140 days and with cyclosporine A, 25-100 mg daily, for 110 days. On examination, she was afebrile and her general condition was well. A 4cm, square, slightly indurated, tender erythema was seen on her left leg. A few 1cm erythe matous eruptions were also seen on her lower extremities. She was prescribed clobetasol propionate ointment. One week later, her erythema enlarged and the induration expanded. Erythema nodosum or Sweet's disease was suspected, and a skin biopsy was taken from her left leg ( Fig. 1A) . Two weeks after the initial visit, the erythema became elevated, and multiple subcutaneous nodules appeared on her extremities. An enlarged lymph node was palpable in her left groin.
The biopsy specimen revealed dense dermal and subcutaneous infiltration of intermediatesized to large atypical lymphoid cells ( Fig. 1B , C) that were CD3/30 + , Granzyme B +/-, EBERISH + , CD4/5/8/20/56 -, TIA -, Perforin -, TCRβ -, TCRγ -, and TCRδ +/-. Plain computed tomography (CT) and positron emission to mography -computed tomography (PETCT) scans showed multiple subcutaneous and intramuscular lesions, and left ing uinal lymph node swelling. No lesion was found in the upper aerodigestive tract. Bone marrow biopsy found 4% of atypical cells and a few haemophagocytic cells. Her peripheral blood had a high concentration of EBV DNA: 120,725 IU/ml. She was diagnosed with ENKTL. Infliximab was discontinued and an L asparaginasebased regimen was started, but it was discontinued because of adverse reactions. She died of the disease 4 months after the diagnosis.
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DISCUSSION
Due to the significant immunosuppressive effects of antiTNF and thiopurine therapy, there have been serious concerns about the increased risk of lymphoma in pa tients with inflammatory bowel disease (IBD) receiving antiTNF and thiopurine therapy (3) (4) (5) (6) . Thiopurines were clearly shown to be associated with increased risk of lymphoma in IBD patients in a prospective observational cohort study (7) and a metaanalysis (8) . However, it is somewhat controversial as to whether antiTNF therapy increases the risk of lymphoma in IBD patients. Some studies have suggested increased lymphoma risk from antiTNF therapy and others have not (3) (4) (5) . At least, we can say that the use of antiTNF with thiopurine, as in the present patient, is thought to be associated with increased risk of lymphoma in patients with IBD (3).
In the present case, the tumour cells were positive for CD3 and negative for CD56. Normal NK cells and most NK cell neoplasms are CD3negative and CD56positive. However, EBVpositive NK/Tcell lymphomas showing typical clinical features and morphological characteris tics with cytotoxic granule protein expression, as in the present case, can be diagnosed as such even if the tumour cells deviate from the classical immunophenotype, for example, the CD3 positivity and CD56 negativity seen in our case (9, 10) . In fact, CD3positive extranodal cytotoxic lymphomas of true Tcell lineage are a well recognized subset of extranodal NK/Tcell lymphoma, nasal type and some cases of them are negative for CD56 (9) .
NK/Tcell lymphoma is thought to be rare in the subcategory of WHO classification "other iatrogenic immunodeficiencyassociated lymphoproliferative dis orders." Nevertheless, we found 2 reports in the English literature of EBVassociated NK/Tcell lymphoma asso ciated with antiTNF therapy. Deneau et al. (11) reported an 11yearold boy who had 12 months of infliximab treatment due to IBD of an undetermined type before he was diagnosed with EBVassociated ENNK/TNT. Summers et al. (12) reported a 15yearold white male with atypical IBD and history of suspected hydroa vacciniforme. He had been treated with infliximab for 25 months before he developed painful subcutaneous nodules and plaques that were eventually diagnosed as EBVassociated ENKTL and aggressiveNKcell lym phoma overlap. Both patients died within one month after the diagnosis. Interestingly, both patients had a history of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA). The present patient had a history of oral aphtha, but none of the other PFAPA symptoms of PFAPA. Notably, shortly before the antiTNF therapy, she had leukocytosis accompanied by disseminated in travascular coagulation that spontaneously remitted. At the time, however, the lymphoma was not detected by bone marrow biopsy or PETCT.
The present case and our review of previous reports suggest that EBVassociated NK/Tcell lymphoma may be a rare, but lifethreatening complication in patients with atypical IBD who receive antiTNF therapy. Ery thematous eruptions or subcutaneous nodules could be the first signs of this rapidly progressing disease. When such symptoms are found, immediate further investiga tion is recommended.
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